Analysis and Interpretation of a Hierarchical Outcome in a Small Pilot Randomized Trial: An Example in the CORTAHF Trial

Clicks: 8
ID: 331645
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #42 of 48 articles by views in European Heart Journal - Cardiovascular Pharmacotherapy

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Aims Hierarchical composite endpoints (HCE) analyzed using generalized pairwise comparisons (GPC) have been increasingly adopted in cardiovascular trials. Stratified, but not covariate-adjusted, win statistics have been frequently presented. We apply methods to a post hoc HCE for the randomized 100-patient CORTAHF pilot trial of short-term corticosteroid therapy in acute heart failure (AHF). Methods and Results The HCE comprised 90-day death, 90-day HF readmission, 30-day worsening HF, and 30-day change in EQ-5D visual analogue scale (EQ-VAS) score from baseline. Win statistics and patient ranks from worst to best outcome were derived from GPC. These ranks were used to produce site-stratified and baseline EQ-VAS-adjusted win odds. Analysis of individual components suggested beneficial prednisone effects on 90-day HF readmission and 30-day WHF adverse events, with little effect on 30-day change in EQ-VAS. The win ratio and win odds were 1.82 and 1.71, respectively (both p<0.05), with 10% ties remaining after most comparisons were resolved at the last tier. HF readmission contributed most to the overall win difference of 26.1%. Stratification and baseline covariate adjustment using patients’ ranks were feasible, but in this example did not substantially alter the estimated win odds. Conclusions Patients’ ranks can be derived from GPC and used to estimate stratified and covariate-adjusted win statistics as well as to visualize the treatment effect. Use of a well-constructed HCE in a small pilot trial should be considered; a positive signal may support further examination of the treatment. A full analysis can aid in interpretation.
Reference Key
openalex_W7220843360 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Jan Biegus, Christopher Edwards, Gary Koch, Gad Cotter, Yonathan Freund, Adriaan A. Voors, Koji Takagi, Piotr Ponikowski, Gerasimos S Filippatos, Ovidiu Chioncel, Matteo Pagnesi, Marco Metra, Douglas L Mann, Beth A. Davison
Are you one of these authors? Claim your profile
Journal European Heart Journal - Cardiovascular Pharmacotherapy
Year 2026
DOI
10.1093/ehjcvp/pvag089
URL
https://academic.oup.com/ehjcvp/advance-article-pdf/doi/10.1093/ehjcvp/pvag089/71646563/pvag089.pdf
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.